CASIA OpenIR  > 中国科学院分子影像重点实验室
Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments
Du, Yang1,2; Liang, Xiaolong3; Li, Yuan1,4; Sun, Ting1,4; Xue, Huadan4; Jin, Zhengyu4; Tian, Jie1,2
2018-02-01
发表期刊CANCER LETTERS
卷号414期号:414页码:230-238
文章类型Article
摘要Programmed death ligand-1 (PD-L1) is a central element in cancer therapies targeting immune checkpoints, and its expression is an important predictor of the therapeutic response. With recent approvals of therapeutic antibodies against PD-L1 and PD-1, noninvasive detection methods are now urgently needed to quantify PD-L1 expression in tumors and to evaluate the response to immune therapies. However, only few such methods are available. Thus, we fabricated nanohybrid liposomal cerasome nanoparticles loaded with the chemotherapeutic drug paclitaxel, and evaluated their value as a theranostic agent. The particles are also decorated with PD-L1 antibody to enable specific targeting, and are dual-labeled to enable near-infrared fluorescence (NIRF) and magnetic resonance imaging (MRI) in vivo. Results showed that in vivo NIRF and MRI imaging following intravenous injection of cerasomes revealed a strong positive contrast for tumors, indicating long-lived enhancement of relevant signals. Moreover, the cerasomes were more effective against tumors and metastasis in comparison to simultaneous but nontargeted delivery of PD-L1 antibody and paclitaxel. Taken together, the data indicate that targeted, dual-labeled cerasomes are good theranostic agents for MRI/NIRF dual-mode detection and treatment of solid tumors in situ. (C) 2017 Elsevier B.V. All rights reserved.
关键词Programmed Cell Death Ligand-1 Near Infrared Fluorescence Magnetic Resonance Imaging Paclitaxel Chemotherapy Immunotherapy
WOS标题词Science & Technology ; Life Sciences & Biomedicine
DOI10.1016/j.canlet.2017.11.019
关键词[WOS]IMMUNE CHECKPOINT BLOCKADE ; CELL LUNG-CANCER ; THERAPY ; IMMUNOTHERAPY ; CHEMOTHERAPY ; TUMORS ; NANOPARTICLES ; COMBINATION ; EXPRESSION ; STABILITY
收录类别SCI
语种英语
项目资助者National Natural Science Foundation of China(81227901 ; Research and Development Program of China (973)(2014CB748600 ; National Key Research and Development Program of China(2017YFA0205200) ; Chinese Academy of Sciences(XDB02060010) ; International Innovation Team of CAS(20140491524) ; Beijing Municipal Science & Technology Commission(Z161100002616022) ; Beijing Natural Science Foundation(Z16110200010000) ; Peking University Third Hospital(BYSY2015023) ; 81470083 ; 2015CB755500) ; 81527805 ; 61231004 ; 81571810 ; 81771846)
WOS研究方向Oncology
WOS类目Oncology
WOS记录号WOS:000419810900024
引用统计
文献类型期刊论文
条目标识符http://ir.ia.ac.cn/handle/173211/19586
专题中国科学院分子影像重点实验室
作者单位1.Chinese Acad Sci, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Inst Automat, Beijing 100190, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100080, Peoples R China
3.Peking Univ, Hosp 3, Dept Ultrasound, Beijing 100191, Peoples R China
4.Beijing Union Med Coll Hosp, Dept Radiol, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Du, Yang,Liang, Xiaolong,Li, Yuan,et al. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments[J]. CANCER LETTERS,2018,414(414):230-238.
APA Du, Yang.,Liang, Xiaolong.,Li, Yuan.,Sun, Ting.,Xue, Huadan.,...&Tian, Jie.(2018).Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.CANCER LETTERS,414(414),230-238.
MLA Du, Yang,et al."Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments".CANCER LETTERS 414.414(2018):230-238.
条目包含的文件 下载所有文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Cancer letter-du.pdf(3002KB)期刊论文作者接受稿开放获取CC BY-NC-SA浏览 下载
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Du, Yang]的文章
[Liang, Xiaolong]的文章
[Li, Yuan]的文章
百度学术
百度学术中相似的文章
[Du, Yang]的文章
[Liang, Xiaolong]的文章
[Li, Yuan]的文章
必应学术
必应学术中相似的文章
[Du, Yang]的文章
[Liang, Xiaolong]的文章
[Li, Yuan]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Cancer letter-du.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。